Literature DB >> 30877073

Sinus surgery improves lower respiratory tract reactivity during aspirin desensitization for AERD.

George X Huang1, Marina L Palumbo2, Joseph I Singer2, Katherine N Cahill3, Tanya M Laidlaw4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 30877073      PMCID： PMC7110416          DOI： 10.1016/j.jaip.2019.02.037

Source DB:  PubMed          Journal:  J Allergy Clin Immunol Pract


× No keyword cloud information.
  11 in total

1.  Medical and surgical considerations in patients with Samter's triad.

Authors:  K Christopher McMains; Stilianos E Kountakis
Journal:  Am J Rhinol       Date:  2006 Nov-Dec

Review 2.  Aspirin-Exacerbated Respiratory Disease.

Authors:  Andrew A White; Donald D Stevenson
Journal:  N Engl J Med       Date:  2018-09-13       Impact factor: 91.245

3.  Montelukast is only partially effective in inhibiting aspirin responses in aspirin-sensitive asthmatics.

Authors:  D D Stevenson; R A Simon; D A Mathison; S C Christiansen
Journal:  Ann Allergy Asthma Immunol       Date:  2000-12       Impact factor: 6.347

4.  Sinus Surgery Is Associated with a Decrease in Aspirin-Induced Reaction Severity in Patients with Aspirin Exacerbated Respiratory Disease.

Authors:  Elina Jerschow; Matthew L Edin; Yuling Chi; Beth Hurst; Waleed M Abuzeid; Nadeem A Akbar; Marc Gibber; Marvin P Fried; Weiguo Han; Teresa Pelletier; Zhen Ren; Taha Keskin; Gigia Roizen; Fred B Lih; Artiom Gruzdev; J Alyce Bradbury; Victor Schuster; Simon Spivack; David Rosenstreich; Darryl C Zeldin
Journal:  J Allergy Clin Immunol Pract       Date:  2018-12-21

Review 5.  Aspirin desensitization in patients with AERD.

Authors:  Donald D Stevenson
Journal:  Clin Rev Allergy Immunol       Date:  2003-04       Impact factor: 8.667

6.  Long-term treatment with aspirin desensitization in asthmatic patients with aspirin-exacerbated respiratory disease.

Authors:  M Pilar Berges-Gimeno; Ronald A Simon; Donald D Stevenson
Journal:  J Allergy Clin Immunol       Date:  2003-01       Impact factor: 10.793

7.  Montelukast protects against nasal lysine-aspirin challenge in patients with aspirin-induced asthma.

Authors:  D K C Lee; K Haggart; F M Robb; B J Lipworth
Journal:  Eur Respir J       Date:  2004-08       Impact factor: 16.671

8.  Long-term treatment with aspirin desensitization: a prospective clinical trial comparing 100 and 300 mg aspirin daily.

Authors:  A Rozsasi; D Polzehl; T Deutschle; E Smith; K Wiesmiller; H Riechelmann; T Keck
Journal:  Allergy       Date:  2008-09       Impact factor: 13.146

9.  The minimally important difference of the Asthma Control Test.

Authors:  Michael Schatz; Mark Kosinski; Aaron S Yarlas; Jennifer Hanlon; Maria E Watson; Priti Jhingran
Journal:  J Allergy Clin Immunol       Date:  2009-09-19       Impact factor: 10.793

10.  Outcomes after complete endoscopic sinus surgery and aspirin desensitization in aspirin-exacerbated respiratory disease.

Authors:  Nithin D Adappa; Viran J Ranasinghe; Michal Trope; Steven G Brooks; Jordan T Glicksman; Arjun K Parasher; James N Palmer; John V Bosso
Journal:  Int Forum Allergy Rhinol       Date:  2017-11-03       Impact factor: 3.858
View more
  8 in total

Review 1.  New concepts for the pathogenesis and management of aspirin-exacerbated respiratory disease.

Authors:  Esha Sehanobish; Mohammad Asad; Elina Jerschow
Journal:  Curr Opin Allergy Clin Immunol       Date:  2022-02-01

2.  Appraisal of the Real-World Effectiveness of Biologic Therapies in Aspirin-Exacerbated Respiratory Disease.

Authors:  Hannah Wangberg; Samantha R Spierling Bagsic; Lilliana Osuna; Andrew A White
Journal:  J Allergy Clin Immunol Pract       Date:  2021-09-28

3.  Mediator production and severity of aspirin-induced respiratory reactions: Impact of sampling site and body mass index.

Authors:  Katherine N Cahill; Pingsheng Wu; Ginger L Milne; Taneem Amin; Joseph Singer; Katherine Murphy; Erin Lewis; Deborah Gapko; Joshua A Boyce; Katherine M Buchheit; Tanya M Laidlaw
Journal:  J Allergy Clin Immunol       Date:  2022-01-11       Impact factor: 14.290

Review 4.  Biomarkers for predicting response to long-term high dose aspirin therapy in aspirin-exacerbated respiratory disease.

Authors:  Lucyna Mastalerz; Katarzyna E Tyrak
Journal:  Clin Transl Allergy       Date:  2021-08-13       Impact factor: 5.871

Review 5.  NSAID-ERD Syndrome: the New Hope from Prevention, Early Diagnosis, and New Therapeutic Targets.

Authors:  Tanya M Laidlaw; Joshua M Levy
Journal:  Curr Allergy Asthma Rep       Date:  2020-03-14       Impact factor: 4.806

Review 6.  The role of aspirin desensitization followed by oral aspirin therapy in managing patients with aspirin-exacerbated respiratory disease: A Work Group Report from the Rhinitis, Rhinosinusitis and Ocular Allergy Committee of the American Academy of Allergy, Asthma & Immunology.

Authors:  Whitney W Stevens; Elina Jerschow; Alan P Baptist; Larry Borish; John V Bosso; Kathleen M Buchheit; Katherine N Cahill; Paloma Campo; Seong H Cho; Anjeni Keswani; Joshua M Levy; Anil Nanda; Tanya M Laidlaw; Andrew A White
Journal:  J Allergy Clin Immunol       Date:  2020-12-09       Impact factor: 10.793

7.  Scoring tool for systemic symptoms during aspirin challenge detects mediator production in aspirin-exacerbated respiratory disease.

Authors:  Patrick J Staso; Pingsheng Wu; Tanya M Laidlaw; Katherine N Cahill
Journal:  Ann Allergy Asthma Immunol       Date:  2021-03-27       Impact factor: 6.248

8.  Biomarkers for predicting response to aspirin therapy in aspirin-exacerbated respiratory disease.

Authors:  Katarzyna E Tyrak; Kinga Pajdzik; Bogdan Jakieła; Izabela Kupryś-Lipińska; Adam Ćmiel; Radosław Kacorzyk; Gabriela Trąd; Piotr Kuna; Marek Sanak; Lucyna Mastalerz
Journal:  Clin Exp Allergy       Date:  2021-05-11       Impact factor: 5.401
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.